A clinical research of Apatinib in the treatment of advanced refractory non-small cell lung cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17011020

Enrollment

Unknown

Registered

2017-03-30

Start date

2017-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

Case series:Apatinib

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. the histologic or cytology confirmed late NSCLC; 2. patients and their families, clear refused surgery and systemic vein chemotherapy; 3. expected lifetime > 3 months, physical status score (ZPS) 0 ~ 3 points; 4. the lungs at least one measurable lesions, the total number of lesions 5 or less; 5. with EGFR or ALK mutations in patients with advanced lung cancer requires corresponding targeted therapy has been confirmed and is now invalid; 6. basic normal heart, liver and kidney function, without, a large number of malignant pleural effusion; Once there is no typical interstitial pneumonia or pulmonary fibrosis; Being patient and family to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Small cell lung cancer (including small cell carcinoma and non-small cell lung cancer); 3. The merger intentional serious primary diseases such as liver and kidney hematopoietic system; 4. People with high blood pressure and antihypertensive drug treatment can't obtain good control (systolic blood pressure > 150 mmHg, diastolic blood pressure > 100 mmHg); With above level II myocardial ischemia or poor control of myocardial infarction, arrhythmia (including QTC period 450 ms or higher) and according to the NYHA standard III-IV cardiac insufficiency; Heart colour to exceed examination: LVEF, left ventricular ejection fraction) < 50%; 5. Can't swallow, chronic diarrhea and intestinal obstruction, significantly affect the drug taking and absorption; 6. With a clear gastrointestinal bleeding concerns (such as local active ulcerative lesions, defecate occult blood + + +), a history of gastrointestinal bleeding within 6 months; 7. Is in or within one month of other clinical trials of patients.

Design outcomes

Primary

Measure	Time frame
DCR;ORR;MST;	—

Secondary

Measure	Time frame
1 year survival rate;	—

Countries

China

Contacts

Public ContactPANDE JIAN

101th Hospital of PLA

pandejian@outlook.com+86 18921150026

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026